Chronic PYY3–36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PYY 3–36 is a gut-derived hormone acting on hypothalamic nuclei to inhibit food intake. We recently showed that PYY 3–36 acutely reinforces insulin action on glucose disposal in mice. We aimed to evaluate effects of PYY 3–36 on energy metabolism and the impact of chronic PYY 3–36 treatment on insulin sensitivity. Mice received a single injection of PYY 3–36 or were injected once daily for 7 days, and energy metabolism was subsequently measured in a metabolic cage. Furthermore, the effects of chronic PYY 3–36 administration (continuous and intermittent) on glucose turnover were determined during a hyperinsulinemic-euglycemic clamp. PYY 3–36 inhibited cumulative food intake for 30 min of refeeding after an overnight fast (0.29 ± 0.04 vs. 0.56 ± 0.12 g, P = 0.036) in an acute setting, but not after 7 days of daily dosing. Body weight, total energy expenditure, and physical activity were not affected by PYY 3–36. However, it significantly decreased the respiratory quotient. Both continuous and intermittent PYY 3–36 treatment significantly enhanced insulin-mediated whole body glucose disposal compared with vehicle treatment (81.2 ± 6.2 vs. 77.1 ± 5.2 vs. 63.4 ± 5.5 μmol·min−1·kg−1, respectively). In particular, PYY 3–36 treatment increased glucose uptake in adipose tissue, whereas its impact on glucose disposal in muscle did not attain statistical significance. PYY 3–36 treatment shifts the balance of fuel use in favor of fatty acids and enhances insulin sensitivity in mice, where it particularly promotes insulin-mediated glucose disposal. Notably, these metabolic effects of PYY 3–36 remain unabated after chronic administration, in contrast to its anorexic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 2×
“Circulating PYY3–36 levels (in fasting and postprandial condition) are low in obese subjects (2, 39, 44), as are the plasma concentrations of several other gut hormones (10, 20, 27, 35).”
BackgroundKoves, T. R., Li, P., An, J., Akimoto, T., Slentz, D., Ilkayeva, O., Dohm, G. L., Yan, Z., Newgard, C. B., & Muoio, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507621200 · Cited by 464
Oxidative Capacity, Lipotoxicity, and Mitochondrial Damage in Type 2 Diabetes
Schrauwen, P., & Hesselink, M. K. C. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1412 · Cited by 408
Attenuated GLP-1 secretion in obesity: cause or consequence
Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394
Central melanocortin receptors regulate insulin action
Obici, S., Feng, Z., Tan, J., Liu, L., Karkanias, G., & Rossetti, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112954 · Cited by 370
Skeletal muscle utilization of free fatty acids in women with visceral obesity.
Colberg, S. R., Simoneau, J. A., Thaete, F. L., & Kelley, D. E. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117864 · Cited by 320
van den Hoek, A. M., Voshol, P. J., Karnekamp, B. N., Buijs, R. M., Romijn, J. A., Havekes, L. M., & Pijl, H. (2004) · Diabetes · doi:10.2337/diabetes.53.10.2529 · Cited by 109
Self-citationMarks, J. L., & Waite, K. (1997) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1997.00554.x · Cited by 80
Cited by
Zhou, J., Martin, R. J., Tulley, R. T., Raggio, A. M., McCutcheon, K. L., Shen, L., Danna, S. C., Tripathy, S., Hegsted, M., & Keenan, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90637.2008 · Cited by 460
The role of peptide YY in appetite regulation and obesity
Karra, E., Chandarana, K., & Batterham, R. L. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164269 · Cited by 336
Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes
Tang, C., Ahmed, K., Gille, A., Lu, S., Gröne, H.-J., Tunaru, S., & Offermanns, S. (2015) · Nature Medicine · doi:10.1038/nm.3779 · Cited by 334
Canfora, E. E., van der Beek, C. M., Jocken, J. W. E., Goossens, G. H., Holst, J. J., Olde Damink, S. W. M., Lenaerts, K., Dejong, C. H. C., & Blaak, E. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-02546-x · Cited by 331
van der Beek, C. M., Canfora, E. E., Lenaerts, K., Troost, F. J., Olde Damink, S. W. M., Holst, J. J., Masclee, A. A. M., Dejong, C. H. C., & Blaak, E. E. (2016) · Clinical Science · doi:10.1042/cs20160263 · Cited by 230
Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?
Esquivel, C. M., Garcia, M., Armando, L., Ortiz, G., Lascano, F. M., & Foscarini, J. M. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3466-7 · Cited by 51
Liu, P. Y., Lawrence-Sidebottom, D., Piotrowska, K., Zhang, W., Iranmanesh, A., Auchus, R. J., Veldhuis, J. D., & Van Dongen, H. P. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab375 · Cited by 28
Metadata
- Authors
- van den Hoek, A. M., Heijboer, A. C., Voshol, P. J., Havekes, L. M., Romijn, J. A., Corssmit, E. P. M., & Pijl, H.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2007-01
- Volume
- 292
- Issue
- 1
- Pages
- E238-E245
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2158474062
- Cited by
- 72
- References
- 9
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.